Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 5% on Monday after the company announced it received 510 (k) clearance from the U.S. Food and Drug Administration for its RNA-based Tempus xR ...

The world of cells is surprisingly noisy. Each cell carries unique genetic information, but when we try to measure cellular ...

The table shows the representative samples and their associated read counts. AutoNormalization effectively normalized the ...

Live-seq brings longitudinal, non-destructive cell sequencing to every lab, revealing new insights into cellular behavior ...

The "United States Next Generation Sequencing Market - Applications & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering.United States Next Generation Sequencing Market is ...

More than 4 million people worldwide have end-stage kidney disease that requires hemodialysis, a treatment in which a machine ...

Tempus AI Inc. shares rose after it said it received 510 (k) clearance from the Food and Drug Administration for its RNA-based in vitro diagnostic device. Its stock recently rose 5.2% to $92.85 in ...

From the moment they're born, newborns—or, specifically, their immune systems—must learn to fight germs without harming their ...

This removes the guesswork inherent to fixed-cycle PCR and ensures that each library is amplified in the best way. iconPCR ...

The world of cells is surprisingly noisy. Each cell carries unique genetic information, but when we try to measure cellular ...